We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Its UK #NationalApprenticeshipWeek, so we've put together a list of our top ten manufacturing apprenticeship schemes led by ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

GSK is moving out of its 635K SF footprint at 14200 Shady Grove Road, where it is the sole tenant, just before its lease ...

The Melbourne-based company on Tuesday posted what chief executive Paul McKenzie described as a robust set of half-year ...

Rockville’s MaxCyte has made its first acquisition in its more than quarter-century of operation. It’s keeping its eyes out ...

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...